PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Etrasimod - Inflammatory bowel disease

PAD Profile : Etrasimod - Inflammatory bowel disease Important

Keywords :
IBD-C, ulcerative colitis, NICE, sphingosine-1-phosphate (S1P) receptor modulator, high cost immunomodulator,
Brand Names Include :
Velsipity
Important Information :
Ulcerative colitis only

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Tablets
Important Information :
NICE guidance applies to Ulcerative Colitis patients only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
ICB
BlueTeq
NICE
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Evidence Review
Etrasimod in UC NICE TA956 Briefing paper May 2024.pdf
Webpage
Etrasimod for treating ulcerative colitis NICE TA956

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
02 October 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found in the IBD guidelines page.

03 May 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves etrasimod as a treatment option in line with the recommendations made in NICE TA956, for treating moderately to severely active ulcerative colitis in people aged 16 years and over.

 

Etrasimod for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

 

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More